PDCD1 and melanoma: These PD‐1 inhibitors have demonstrated significant therapeutic efficacy in multiple malignancies, including melanoma, non‐small‐cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC), supported by robust clinical evidence and extensive real‐world experience [9, 10].